Nestle S.A. / Aimmune Therapeutics, Inc.

Peanut Allergy in Children and Adolescents (4-17 years)

1.8M US cases/yr · $2.0B Global food allergy therapeutics market 2020 (with peanut as anchor) · ~$2.6B Fully diluted equity acquisition value at $34.50/share (174% premium to 8/28/20 close)

Disease Overview

Peanut allergy is the most common food allergy among U.S. children and a leading cause of anaphylaxis-related emergency department visits and food-related fatalities. Approximately 1.5-2 million U.S. children and adolescents (ages 4-17) have peanut allergy — roughly 2.5% of U.S. children, with prevalence having more than tripled over the past 25 years. The pathophysiology is IgE-mediated Type I hypersensitivity to Ara h proteins (Ara h 1, 2, 3, 6) in peanut, with mast cell degranulation triggering anaphylaxis on accidental exposure. Standard of care prior to Palforzia approval (January 2020) was strict avoidance plus rescue epinephrine (EpiPen, Auvi-Q, generic) for accidental exposure. Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp; AR101) is the first FDA-approved peanut allergy oral immunotherapy (OIT), delivered as a defatted peanut flour drug product administered in a structured, escalating-dose protocol over 6+ months to induce desensitization. The therapy reduces severity of allergic reactions to accidental peanut exposure but requires lifelong daily dosing and does not cure underlying allergy. WAC pricing is ~$890/month ($10,680/year). Nestle's strategic premise: Palforzia anchors the Nestle Health Science platform of personalized nutrition and food allergy interventions, complementing Nestle's earlier acquisitions of Vitaflo (medical nutrition), Aimmune Therapeutics (allergy), and Aimmune's broader OIT pipeline (egg, walnut). The acquisition was ultimately challenged by slow Palforzia uptake — Nestle wrote down the asset in 2023 and divested it to Stallergenes Greer in 2024.

Competitive Landscape

The peanut allergy and broader food allergy competitive landscape splits between rescue epinephrine, oral immunotherapy (OIT), and emerging biologic and modality alternatives. Rescue therapy is dominated by epinephrine auto-injectors — EpiPen (epinephrine, Mylan/Viatris), Auvi-Q (epinephrine, Kaleo), and generic epinephrine auto-injectors (Teva, Mylan), with neffy (epinephrine nasal spray, ARS Pharmaceuticals) approved August 2024 as the first needle-free option. Approved disease-modifying therapy is Palforzia (Aimmune/Nestle, peanut OIT) — first-in-class but with disappointing commercial uptake. Pipeline includes biologics — Xolair (omalizumab, anti-IgE, Roche/Genentech) FDA-approved February 2024 for IgE-mediated food allergy as a non-allergen-specific systemic option; this approval substantially undercut Palforzia's commercial trajectory. Investigational entrants include sublingual immunotherapy (SLIT) approaches — DBV Technologies' Viaskin Peanut (epicutaneous patch, EPIT, Phase 3 EPITOPE positive 2022); ARO-1689 (Allergy Therapeutics, peptide immunotherapy); and Camallergy's CA002. Adjacent biologic competitors include Regeneron/Sanofi's Dupixent (dupilumab, anti-IL-4Rα, off-label use), and Genentech's anti-IgE EBI-005. Nestle ultimately divested Palforzia to Stallergenes Greer in September 2024 after writedowns, validating concerns that adoption barriers (complex titration protocol, low willingness-to-pay, allergist channel friction) outweighed clinical benefit.